Downstream targets of SSRI effect in treatment of Major Depressive Disorder
- Conditions
- Major depressive disorder (MDD)Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Registration Number
- EUCTR2019-002232-82-SE
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Not specified
- Target Recruitment
- 20
•age 20-80 years
•ongoing major depressive episode according to M.I.N.I. interview
• healthy, apart from MDD, according to MRI, clinical interview, physical examination, blood tests (Hb, ASAT, ALAT, GT, Na, K, creatinine, calcium, albumin, TSH, glucose).
•MADRS>20
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5
•ongoing pharmacological treatment (wash out-time one month, drugs not used for MDD treatment and without serotonergic effect may be allowed at the discretion of the PI)
•bipolar disorder
•psychotic syndrome
•alcohol/drug dependence
•organic central nervous system disorder
•patient who is not suitable for MRI (claustrophobia, MRI incompatible metal implants)
•pregnancy.
•Allergy or hypersensitivity to escitalopram
•Ongoing treatment with any medication that is known to prolong the QT interval
•Ongoing treatment with any monoamine oxidase inhibitor
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method